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Abstract
Ultraviolet light (UV) is an important risk factor for cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma
and cutaneous melanoma of the skin. These cancers most commonly affect persons with fair skin and blue eyes who
sunburn rather than suntan. However, each of these cancers appears to be associated with a different pattern of UV
exposure and to be mediated by different intracellular molecular pathways.
Some melanocortin 1 receptor (MC1R) gene variants play a direct role in the pathogenesis of cutaneous basal cell
carcinoma, cutaneous squamous cell carcinoma and cutaneous melanoma apart from their role in determining a
cancer-prone pigmentory phenotype (fair skin, red hair, blue eyes) through their interactions with other genes
regulating immuno-inflammatory responses, DNA repair or apoptosis.
In this short review we focus on the aetiological role of UV in cutaneous basal cell carcinoma, cutaneous squamous cell
carcinoma and cutaneous melanoma of the skin, and on some associated biopathological events.
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Background
The skin of the head and face is habitually exposed to
sunlight and there may consequently be ultraviolet
(UV)-induced chronic damage such as solar elastosis, ac-
tinic keratosis and lentigo, with possible consequent de-
velopment of cutaneous squamous cell carcinoma,
cutaneous basal cell carcinoma and cutaneous melan-
oma [1].
Cutaneous squamous cell carcinoma originates from
stem/progenitor cells of the basal cell layer of the epider-
mis and cutaneous basal cell carcinoma from either the
bulge region of hair follicle which is rich in keratinocyte
stem cells or from stem/progenitor cells of the basal cell
layer of the epidermis [2, 3]. While the origin of melan-
oma cells is unknown, it has been proposed that cutane-
ous melanoma precursor cells may arise either from
dedifferentiated melanocytes or from melanocyte
progenitors in the bulge region of hair follicles, or from
neural crest-derived Schwann cell precursors [1–4].
Cutaneous squamous cell carcinoma of the skin is as-
sociated with frequent moderate chronic UV exposure,
and is often preceded by premalignant actinic keratosis
or by Bowen disease. On the other hand, cutaneous
basal cell carcinoma is usually associated with intermit-
tent, infrequent, intense UV exposure and almost invari-
ably arises de novo [1, 5–7]. Cutaneous melanoma can
also arise de novo after intermittent, infrequent, intense
UV exposure, but there is evidence that as many as 30 %
of cases evolve from pre-existing sites of melanotic pig-
mentation, whether or not they have actually been ex-
posed to UV [4].
Both cutaneous squamous cell carcinoma and melan-
oma are very likely to metastasize whereas cutaneous
basal cell carcinoma very seldom does [5]. Even in the ab-
sence of exposure to UV, squamous cell carcinoma is oc-
casionally associated with non-healing wounds or
scarring, or with chronic lesions which are, or have been
preceded by chronic immuno-inflammatory processes.
This is not the case with cutaneous basal cell carcinoma
or cutaneous melanoma. Cutaneous squamous cell
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carcinoma, basal cell carcinoma and melanoma more fre-
quently affect elderly, red haired, blue eyed and fair com-
plexioned persons [7], and it has been consistently
demonstrated that variants of the highly polymorphic
melanocortin 1 receptor (MC1R) gene are associated
with increased risk of these malignancies [8].
The pathogenesis of cutaneous squamous cell carcin-
oma is associated with multiple local genetic alterations
that may bring about dysregulation of the cell cycle, of
apoptosis, of DNA repair, of cellular differentiation, of
telomerase activity with evasion of cellular senescence,
and of expression of the enzyme cyclo-oxygenase 2
(COX-2).
In contrast, cutaneous basal cell carcinoma is pri-
marily driven by genetic mutations causing uncontrolled
activation of the hedgehog intracellular pathway lead-
ing to enhanced proliferative capacity of basal cells,
and by molecular alterations in the p53 tumour-
suppressor gene [9]. Most cases of cutaneous basal
cell carcinoma occur sporadically, but they may also
occur as a manifestation of the rare heritable basal
cell nevus syndrome in association with germline
molecular aberrations of the hedgehog intracellular
signalling pathway [5].
Melanomas of the skin of the head and face are usually
of the lentigo maligna type which is commonly associ-
ated with frequent, moderate chronic UV exposure. This
is in contrast to melanomas of the trunk, for example,
which are associated with intermittent, acute UV expos-
ure. Skin melanoma cells show molecular alterations of
the RAS-BRAF-MEK-ERK mitogen activated protein
kinase (MAPK) signalling pathway, mediating uncon-
trolled proliferation of the affected malignant melano-
cytes; genetic alterations in the CDKN2A gene encoding
the p16INK4A tumour suppressor protein; and MC1R
genetic polymorphism [1, 10, 11]. In 10-30 % of cases,
cutaneous melanoma arises from pre-existing melan-
otic hyperpigmentations such as lentigo, freckles or
pigmented naevi. Despite an established cause-and-
effect relationship between the development of mel-
anoma and exposure to UV, genes with UV-induced
‘signature mutations’ are not common in melanoma
[1]. Thus, it is evident that the aetiopathogenesis of
melanoma is complex, with UV playing a critical
role, but UV by itself does not necessarily cause
melanoma. Indeed, in Black people, melanomas
mainly affect body sites that are not exposed to UV
such as the soles of the feet and the palms of the
hands (acral melanoma) [12].
The purpose of this short review is to shed some light
on the relationship between exposure to UV and cutane-
ous squamous cell carcinoma, basal cell carcinoma, and
melanoma, and to discuss some aspects of the biopathol-
ogy of these cancers.
Melanocortin 1 receptor (MC1R) and its role in the
pathogenesis of cutaneous squamous cell
carcinoma, cutaneous basal cell carcinoma and
cutaneous melanoma
The MC1R gene plays an important role in melanin pro-
duction and in skin pigmentation. Pro-opiomelanocortin
(POMC) and its derivatives, particularly α-melanocyte
stimulating hormone (αMSH) are agonistic ligands of
MC1R on melanocytes, mediating the biosynthesis of
both red-yellow pheomelanin and brown-black eumela-
nin. Melanins are synthesized in melanosomes which are
transported to the extremities of the melanocytic den-
drites via microtubuli, and are ultimately transferred to
neighbouring keratinocytes where they protect keratino-
cytes from UV-induced DNA damage [13, 14].
The MC1R gene is highly polymorphic among White
people with some genetic variants mediating the produc-
tion of more pheomelanin and less eumelanin, resulting in
the phenotype of red hair, blue eyes and fair skin [13, 15].
Persons with a phenotype mediated by one of these
MC1R genetic variants are at greater risk of UV-induced
skin cancers, because pheomelanin not only provides less
effective protection against UV than does eumelanin, but
it also generates more mutagenic free radicals in response
to UV.[16] Apart from their role in determining a cancer-
prone pigmentory phenotype, it has been demonstrated
that certain MC1R variants play a direct role in the patho-
genesis of cutaneous squamous cell carcinoma, cutaneous
basal cell carcinoma and cutaneous melanoma [5, 13, 16].
In fact, about 15 % of all cases of cutaneous melanoma are
associated with some MC1R variants [17].
Non-pigmentory functions of MC1R mediated via the
αMSH/MC1R pathway include regulation of local
immuno-inflammatory responses brought about by several
factors including modulation of NF-κB which is an import-
ant regulator of the production of inflammatory mediators
[18, 19], mediation of the proliferation and survival of me-
lanocytes [20], induction of DNA repair following UV-
induced DNA damage [19–21], and diminution of oxida-
tive stress by reducing the generation of reactive oxidative
species that have the capacity to cause oxidative damage
to cellular DNA [22].
In response to DNA damage caused by UV, there is
stimulation of the keratinocytic p53 gene leading to
transcriptional activation of αMSH inducing DNA repair
mechanisms mediated through xeroderma pigmentosum
proteins [23, 24]. In melanocytes, UV induces both the
upregulation of expression of MC1R and the production
of αMSH, that via the MC1R/αMSH/cAMP pathway ac-
tivates DNA repair mechanisms [21] and diminishes oxi-
dative stresses [22, 25]. This prevents the development
of genomic instability in response to UV, and minimizes
the risk of UV-induced malignant transformation of me-
lanocytes [22].
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These non-pigmentory functions outlined in the above
two paragraphs are dysregulated in melanocytes express-
ing those MC1R variants, thus promoting the risk of
melanoma [13, 16, 20, 21]. In fact, compared to melano-
cytes with mainstream MC1R it has become clear that in
response to UV-induced DNA damage, melanocytes with
MC1R variants have a lower DNA repair capacity, more
DNA mutagenic photoproducts, increased oxidative DNA
damage, and decreased apoptosis [21, 25]. Thus, the risk of
melanoma is polygenetic comprising interactions between
MC1R variants, other pigmentory gene variants, dysfunc-
tional DNA repair genes and immuno-inflammatory genes
[19, 26].
Cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma frequently affects eld-
erly White people with a phenotype of red hair, blue eyes
and fair skin, who for a long time have been chronically ex-
posed to UV. In keratinocytes, UV induces two major
classes of mutagenic photoproducts: cyclobutane-
pyrimidine dimers (CPDs), and 6,4 pyrimidine-pyrimidine.
These DNA lesions may give rise to the genetic mutations
C→T and/or CC→TT that are the hallmarks of UV-
induced mutagenesis, and are considered to be ‘UV signa-
ture mutations’ [12, 27, 28]. Furthermore, in sun-exposed
skin, UV can induce the generation of highly reactive oxy-
gen species with the capacity to cause DNA damage, thus
further promoting mutagenesis [27, 29].
In general, if the damage to DNA affects oncogenes,
tumour-suppressor genes (anti-oncogenes), or cell cycle
checkpoint control genes, cellular genomic integrity will be
destabilized with increased risk of acquiring additional cyto-
genetic alterations. Molecular alterations in oncogenes may
permit uncontrolled cell proliferation in response to micro-
environmental growth signals; and in tumour suppressor
genes may result in dysregulated oncogenic activity. Mo-
lecular alterations in cell cycle checkpoints may prevent ar-
rest of the cell cycle that is necessary to allow DNA repair,
or may prevent apoptosis in response to DNA damage
which exceeds the cellular DNA repair capacity, with the
outcome of propagation of the altered DNA by cell division
of the transformed cells [30, 31]. Since some of these trans-
formed cells are metabolically fitter and have a selective
growth advantage over the normal neighbouring cells [32],
they will ultimately undergo clonal expansion, and spread
at the expense of the normal surrounding keratinocytes
[31], creating a field or multiple fields of precancerized
epidermis comprising cytogenetically-altered keratinocytes
at different stages of transformation.
Such a field of precancerized epidermis with molecularly
altered keratinocytes may look clinically normal and may
or may not have the microscopical features of UV-
induced damage (i.e. solar elastosis, epidermal dysplasia),
or may exhibit the clinical and histopathological features
of actinic keratosis which is a precursor lesion of cutane-
ous squamous cell carcinoma [33]. Subsequent clonal
divergence will result in the evolution of subclones which
would have had multiple episodes of genetic mutations,
one or more of which will eventually give rise to frank cu-
taneous squamous cell carcinoma in all its clinical variety
[33].
The dermis/stroma plays an important role in the
pathogenesis of squamous cell carcinoma. At the inter-
face between epidermis and dermis/stroma, lies the
basement membrane which initially prevents the tumour
from invading the underlying connective tissue. The
degradation of collagen, particularly collagen type IV, in
the basement membrane is crucial for the infiltration of
the underlying connective tissue by the tumour cells and
is achieved by the matrix metalloproteinases (MMP)-2
and 9 [34]. Increased expression of MMP-2 is found in
the stroma of squamous cell carcinoma compared with
that of basal cell carcinoma and may thus be responsible
for the different pattern of invasion found in these two tu-
mours [35]. Metastasis to lymph nodes is also said to be
assisted by these MMPs [34, 36]. Depletion of collagen VI,
which is a component of the fibrils which anchor the base-
ment membrane to the dermis, promotes invasion and
epithelial-mesenchymal transition of keratinocytes [37].
Once the basement membrane has been breached by
the tumour cells, they become associated with a multi-
cellular tumoural environment which is essential in
modulation of the tumour and in its metastasis. An im-
portant cell type in this milieu is the cancer-associated
(myo-) fibroblast (CAF), identified by the presence of α-
smooth muscle actin [38, 39] and which occurs profusely
in the tumour environment [40]. The restructuring of
the extracellular matrix which facilitates invasion occurs
by the production of chemokine ligand 7 by the CAFs
[41]. This is in contrast to connective tissue growth fac-
tor (CTGF) which promotes mesenchymal to epithelial
transition and suppresses invasiveness [42] in head and
neck squamous cell carcinoma.
Cutaneous basal cell carcinoma
Cutaneous basal cell carcinoma is the most common
cancer in White people [9, 43]. It is so named because
the cells of basal cell carcinoma resemble the cells of the
basal cell layer of the epithelium [5]. Cutaneous basal
cell carcinoma affects mainly chronically sun-exposed
skin of the head and neck of fair complexioned older
people. Both intermittent acute, and long standing con-
tinual exposure to UV are high risk factors for cutaneous
basal cell carcinoma. It is a slow-growing cancer that if left
untreated will invade locally, but only rarely metastasizes.
Black people are rarely affected. People with cutaneous
basal cell carcinoma are at increased risk for cutaneous
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squamous cell carcinoma and cutaneous melanoma [5, 9,
11, 43].
Dysregulation in the hedgehog intracellular signalling
pathway is implicated in the pathogenesis of cutaneous basal
cell carcinoma and is thought to be an early genetic factor
in its tumourigenesis [44]. The hedgehog signalling pathway
plays an essential role in organogenesis, and later, postna-
tally, in regulating proliferation and differentiation of kera-
tinocyte stem cells, and in the development of hair follicles
and sebaceous glands [1]. In the hedgehog signalling path-
way, patch 1 (PTCH1) functions as a tumour suppressor
gene, inhibiting the activity of the proto-oncogene, smooth-
ened (SMO). Signalling by SMO results in activation of tran-
scription of hedgehog target genes, eliciting mitogenic
responses with increased proliferation of keratinocyte stem
cells. Clonal expansion of dysregulated cells within the kera-
tinocytes stem cell niche is favoured by loss-of-function mu-
tation in PTCH1 that allows upregulated activity of SMO,
and by gain of function mutations in the SMO gene that
render SMO protein resistant to inhibition by PTCH1.
These promote escape of cancer precursor cells from the
niche to colonize other cellular compartments in the skin,
ultimately giving rise to a basal cell carcinoma [9, 11, 45].
The molecular alterations in the hedgehog signalling
pathway may be of germline origin or may occur postna-
tally subsequent to UV-induced DNA damage, or rarely
may arise spontaneously [11, 46]. Keratinocytes which
show dysregulated expression of the hedgehog signalling
pathway fail to undergo cell-cycle arrest in response to
the p21 cell cycle inhibitor, and thus have enhanced pro-
liferative capacity [6]. It has been reported that most
cases of cutaneous basal cell carcinomas that arise spon-
taneously show loss of function of PCTH1 and a minor-
ity show enhanced function of SMO [5]. About half of
all cases of sporadic basal cell carcinoma also show
mutations in the p53 tumour suppressor gene, but
these seem to be late genetic events in the tumouri-
genesis of cutaneous basal cell carcinoma, which are
related to its progression [45, 47]. Taking advantage
of the inhibition of the hedgehog signalling pathway
as a mean of treatment of cutaneous basal cell carcin-
oma of the skin has become possible through the use
of an inhibitor, vismodegib (GDC-0049) and other
hedgehog pathway antagonists [48].
Cutaneous basal cell carcinoma requires a specific
stromal environment to maintain its morphological
characteristics [49]. Key regulators of the biological
behaviour of cutaneous basal cell carcinoma appear
to be stromal fibroblasts and myofibroblasts [49].
Cutaneous basal cell carcinoma cells express bone
morphogenetic protein (BMP) 2 and 4, while GREM-
LIN 1, a BMP antagonist is highly expressed in the
stroma of the tumour but not in the dermis under-
lying normal keratinocytes. GREMLIN 1 counteracts
the growth-inhibitory effect of BMPs and is therefore
assumed to be an important agent supporting cuta-
neous basal cell carcinoma cell proliferation and sur-
vival. Matrix metalloproteinase expressed in the
stroma of cutaneous basal cell carcinoma also plays
an important role in regulating growth and other
functions of cutaneous basal cell carcinoma cells [6].
It is probable that cutaneous basal cell carcinoma tumour-
igenesis depends substantially on specific factors produced
by stroma damaged by UV, but on the rare occasions
when cutaneous basal cell carcinomas occur at sites that
are not exposed to sunlight, other biological factors drive
its initiation and progression [5].
Although UV-radiation is a primary aetiological factor for
cutaneous basal cell carcinoma, the mechanism whereby
exposure to UV triggers cutaneous basal cell carcinoma is
complex and the details are as yet unknown [5]. The
development of cutaneous basal cell carcinoma at sites not
exposed to UV is unexplained. Cutaneous basal cell carcin-
oma usually develops at sites continually exposed to UV
which explains why basal cell carcinoma so frequently af-
fects the skin of the head and face [5, 9, 50, 51].
Reduced functional activity of genes regulating repair of
DNA damaged by UV may be a modifying factor in the
pathogenesis of cutaneous basal cell carcinoma [5]. In
support of this, subjects with the genetic condition, xero-
derma pigmentosum in whom there are high-penetrance
germline mutations in genes encoding proteins involved
in the mechanism of nucleotide excision-repair are at
great risk of developing multiple and recurrent cutaneous
basal cell carcinomas at a young age [5, 52].
In contrast to subjects not affected by basal cell carcin-
oma, those who do have basal cell carcinoma show reduced
clearance of mutagenic photoproducts from UV-induced
DNA lesions of sunlight exposed skin [5], probably owing
to low-penetrance genetic polymorphisms of specific genes
encoding enzymes involved in breaking down reactive
oxygen species and DNA repair [32].
Cutaneous melanoma
Cutaneous melanoma is an aggressive skin tumour that
can be classified into 4 main subtypes: superficial spread-
ing, nodular, lentigo maligna and acral melanoma. Lentigo
maligna melanoma typically affects long-term chronically
UV-exposed skin of the head and face [53], where other
subtypes are relatively rare [29]. The frequency of lentigo
maligna melanoma increases with age and peaks in the
seventh to eighth decades of life [10, 54]. Lentigo maligna
is an epithelial field of atypical melanocytes which takes
the form as an ill-defined brown macule which slowly
expands centrifugally. When these atypical epithelial
melanocytes breach the basement membrane and invade
the connective tissue, the lesion is referred to as lentigo
maligna melanoma [54]. Cutaneous melanomas of the
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head and neck are less likely to arise in association with
pre-existing pigmented nevi than cutaneous melanomas
of the trunk [55].
Many complex factors are implicated in the pathogen-
esis of cutaneous melanoma including family history,
phenotypic characteristics such as pale skin and red hair
with propensity to sunburn, many episodes of sunburn es-
pecially in youth, the presence of numerous melanotic
nevi or freckles, and pre-existing dysplastic nevi. Further
factors are MC1R genetic polymorphism, and perhaps
other yet ill-defined environmental factors [29, 56], but
some MC1R variants are associated with increased risk of
cutaneous melanoma regardless of skin type and hair
colour [16, 20].
Like cutaneous squamous cell carcinoma, lentigo maligna
melanoma typically affects chronically UV-exposed skin of
the head and face, but the risk of other subtypes of melan-
oma is more related to intermittent, intense UV exposures
[51, 53, 54].
In contrast to malignant keratinocytes of cutaneous squa-
mous cell carcinoma that show UV-induced signature-
mutations, these are rare in cutaneous melanoma cells [12],
and while mutations to tumour-suppressor gene p53 are
frequent in UV-induced squamous cell carcinoma, in UV-
induced cutaneous melanoma they are not [12]. Cutaneous
melanoma cells but not malignant keratinocytes show
oncogenic mutations in either NRAS or BRAF. Except for
acral and mucosal melanomas, BRAF mutations are an
early genetic event of melanoma tumourigenesis and can
be found in up to 60 % of frank melanomas [22, 57]. In
contrast, in mucosal and acral melanomas there are gain-
of-function mutations in the cKit receptor thyrosine kinase
[4]. Inactivating mutations in the CDKN2A gene which en-
codes for p16INK4a tumour suppressor protein, pose a
high risk for development of cutaneous melanoma [12, 58].
Both BRAF and CDKN2A mutations in cutaneous melan-
oma cells are characteristic of indirect UV-induced oxida-
tive damage [25].
Cutaneous melanoma arising from melanocytes residing
in the basal cell layer of the epidermis usually shows one of
two histopathological patterns. In one pattern there is a ra-
dial growth phase characterized by proliferation of atypical
melanocytes within the epidermis and by small breaches of
the basement membrane. In the other pattern there is a
phase of ‘vertical’ growth which occurs once the basement
membrane is breached and the melanoma starts to invade
the dermis in a nodular pattern without any significant pre-
ceding phase of radial growth [4]. A further third pattern of
growth occurs when the cutaneous melanoma originates
from melanocyte precursors that reside in the dermis as a
result of arrest in their migration from the neural crest. In
this case, epidermal melanocytes do not contribute to the
cutaneous melanoma and there is no evidence of invasive
breaching of the basement membrane [4].
Cutaneous melanoma is rare in Black persons, and when
it occurs, it preferentially affects body sites not habitually
exposed to UV such as the sole of the foot, the palm of the
hand and the nail bed (acral melanomas). Although the
dorsum of the hand is usually constantly exposed to UV-
radiation, for some obscure reasons it is only rarely affected
by cutaneous melanoma [53]. Curiously, while the fre-
quency of cutaneous basal cell carcinoma and cutaneous
squamous cell carcinoma is high in albino Blacks, cutane-
ous melanoma is rare in this population group [59, 60].
There is evidence of loss of integrity of membranes of
the melanosomes in melanoma cells with consequent
leakage of reactive oxygen species (ROS) and metabolic
by-products of melanogenesis that may be cytotoxic,
genotoxic or mutagenic into the cytoplasm of melanoma
cells contributing to progressive DNA damage [61]. It is
possible that the primary alterations to DNA, favouring
initial transformation of normal melanocytes and later
promoting malignant transformation of the initially
transformed melanocytes may result from a similar loss
of integrity of the membranes of melanosomes within
normal melanocytes [4, 61, 62].
UV-induced immunosuppression
It is known that the immune system has the capacity to
recognize and to react to immunogenic cells in any
population of tumour cells. T cell-mediated immune re-
sponses against tumour-specific antigens may directly
cause lysis of tumour cells, and activated inflammatory
cells may non-specifically destroy tumour cells by pro-
ducing and secreting active biological mediators [63].
Both in dark and in light skin, UV can cause local im-
mune suppression by altering antigen presentation by
Langerhans cells, and by increasing expression of im-
munosuppressive neuropeptides, melanocortins, cytokines
and inflammatory mediators released into the microenvir-
onment by keratinocytes, melanocytes, neurocytes and
mast cells [29, 64, 65]. This may diminish the capacity of
the immune system to detect and to eliminate immuno-
genic initially transformed keratinocytes and melanocytes,
and so to promote the growth of cutaneous basal cell car-
cinoma, cutaneous squamous cell carcinoma and cutane-
ous melanoma [29].
Conclusion
The risk of non-syndromal cutaneous basal cell carcin-
oma, cutaneous squamous cell carcinoma and cutaneous
melanoma is associated with UV exposure, but the com-
plex multifactorial relationship between the patterns of
exposure to UV and the pathogenesis of these skin
cancers is yet to be explained. However, it is established
that polymorphic low-penetrance pigmentory genes gov-
erning pigmentation, genes involved in the mechanisms
of breaking down UV-induced reactive oxygen species,
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genes encoding DNA-repair proteins, and UV-induced
genetic mutations, all interact on a background of UV-
induced local immunosuppression and other genetic and
environmental factors in the initiation and progression
of these malignancies.
Thus, susceptibility to sporadic cutaneous basal cell
carcinoma, cutaneous squamous cell carcinoma and cu-
taneous melanoma is a polygenetic trait with each low-
penetrance genetic variant contributing to the overall
carcinogenic effect, and with extrinsic factors having the
capacity to modify cancer risk by influencing the pene-
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